font size
Sign inprintPrint

DRUG DEVELOPMENT:

Remarkable Result in Melanoma Drug Trial

Study drug shrinks tumors in 81 percent of melanoma patients.


Plexxikon said its experimental drug, the subject of a collaboration with Roche, was able to shrink melanoma tumors in 81 percent of patients in an early-stage trial. The positive results were short-lived. Tumors grew again in all but two of the trial patients following the treatment. But researchers have hailed the result as a breakthrough in treating the notoriously tough-to-treat cancer.
Read More
Other recent stories